Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).

PHASE4CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Epilepsy
Interventions
DRUG

Pregabalin

"Pregabalin treatment, given as 2 divided doses, is initiated at a dose of 150 mg/day (75 mg BID).~Based on individual subject response and tolerability, the dosage may be increased to 300 mg/day after 1 week (150 mg BID given as two 75-mg capsules BID). Based on subjects individual response and tolerability, dosage can be incrementally increased further after an additional week to 600 mg/day (300 mg BID given as four 75-mg capsules BID)."

Trial Locations (8)

11526

Pfizer Investigational Site, Athens

11527

Pfizer Investigational Site, Athens

15125

Pfizer Investigational Site, Mesogion, Athen

26500

Pfizer Investigational Site, Pátrai

54636

Pfizer Investigational Site, Thessaloniki

57010

Pfizer Investigational Site, Thessaloniki

71110

Pfizer Investigational Site, Heraklio

Unknown

Pfizer Investigational Site, Thessaloniki

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00288639 - Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER). | Biotech Hunter | Biotech Hunter